King Levoxyl NDA Approval Anticipated In May Ahead of FDA August Deadline
Executive Summary
King expects FDA to approve its Levoxyl NDA by the end of May, the company's President and Chief Operating Officer Jeff Gregory said during a conference call Feb. 20.
You may also be interested in...
Abbott Synthroid NDA To Include Clinical Study Data; Citizen Petition Rejected
Abbott will file data from clinical studies, including bioavailability and pharmacokinetic data, to support its NDA for the thyroid agent Synthroid.
Abbott Synthroid NDA To Include Clinical Study Data; Citizen Petition Rejected
Abbott will file data from clinical studies, including bioavailability and pharmacokinetic data, to support its NDA for the thyroid agent Synthroid.
Watson Moves Reps To Women's, General Divisions For Branded Launches
Watson Pharmaceuticals is shifting sales reps from its dermatology division to support product launches in its general products and women's health divisions.